

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Psychotropic Medications Polypharmacy Clinical Edit
<b>First Implementation Date:</b>	November 5, 2010
<b>Proposed Date:</b>	September 16, 2021
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate and prudent use psychotropic medications

**Why Issue Selected:** MO HealthNet will assess the usage of psychotropic agents in the pharmacy program with a primary goal of patient safety in regard to polypharmacy or use of more drugs than is medically necessary. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and, by using medical evidence guidelines, this clinical edit can flag potentially dangerous duplication within drug classes, dangerous drug interactions, or overmedication. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Psychotropic medications
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Demonstrated compliance to prescribed therapy (90 out of 120 days) for participants  $\geq 18$  years of age who are not enrolled in foster care **OR**
- Participant  $\leq 5$  years of age: history of  $\leq 3$  different psychotropic medications in the past 60 days **OR**
- Participant  $\geq 6$  years of age: history of  $\leq 5$  different psychotropic medications in the past 60 days
- Documented diagnosis of a seizure disorder: all seizure medications are not counted in a participant's past history of psychotropic medications

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:

  

Progress Notes:  
Other:

  

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

6 months

## Appendix A – Agents in the Psychotropic Medications Polypharmacy Clinical Edit

Psychotropic Medications
ALPRAZOLAM
AMITRIPTYLINE HCL
AMITRIPTYLINE/CHLORDIAZEPOXIDE
AMOBARBITAL SODIUM
AMOXAPINE
AMPHETAMINE
AMPHETAMINE SULFATE
ARIPIPRAZOLE
ARIPIPRAZOLE LAUROXIL
<b>ARIPIPRAZOLE LAUROXIL, SUBMICRONIZED</b>
ARMODAFINIL
AZENAPINE
AZENAPINE MALEATE
ATOMOXETINE HCL
<b>BREMELANOTIDE ACETATE</b>
BREXPIPRAZOLE
BRIVARACETAM
BUPROPION HBR
BUPROPION HCL
BUSPIRONE HCL
BUTABARBITAL SODIUM
<b>CANNABIDIOL (CBD)</b>
CARBAMAZEPINE
CARIPRAZINE HCL
<b>CENOAMATE</b>
CHLORDIAZEPOXIDE HCL
CHLORDIAZEPOXIDE/CLIDINIUM BR
CHLORPROMAZINE HCL
CITALOPRAM HYDROBROMIDE

### SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

<b>Psychotropic Medications Continued</b>
CLOBAZAM
CLOMIPRAMINE HCL
CLONAZEPAM
CLONIDINE HCL
CLORAZEPATE DIPOTASSIUM
CLOZAPINE
DESIPRAMINE HCL
DESVENLAFAXINE
<b>DESVENLAFAXINE FUMARATE</b>
DESVENLAFAXINE SUCCINATE
<b>DEUTETRABENAZINE</b>
DEXMETHYLPHENIDATE HCL
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE/AMPHETAMINE
DIAZEPAM
DIVALPROEX SODIUM
DOXEPIN HCL
<b>DROPERIDOL</b>
DULOXETINE HCL
ESCITALOPRAM OXALATE
<b>ESKETAMINE HCL</b>
ESLICARBAZEPINE ACETATE
ETHOSUXIMIDE
ETHOTOIN
<b>EZOGABINE</b>
FELBAMATE
<b>FENFLURAMINE HCL</b>
<b>FLIBANSERIN</b>
FLUOXETINE HCL
FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL
FLUVOXAMINE MALEATE
FOSPHENYTOIN SODIUM
GABAPENTIN
GABAPENTIN ENACARBIL
GABAPENTIN/LIDOCAINE
<b>GABAPENTIN/LIDOCAINE HCL/GAUZE BANDAGE/S</b>
<b>GABAPENTIN/LIDOCAINE HCL/MENTHOL</b>
<b>GABAPENTIN/LIDOCAINE HCL/SILICONE ADHESI</b>
<b>GABAPENTIN/LIDOCAINE/PRILOCAINE/TRANSPAR</b>
GUANFACINE HCL
HALOPERIDOL
HALOPERIDOL DECANOATE
HALOPERIDOL LACTATE
ILOPERIDONE
IMIPRAMINE HCL
IMIPRAMINE PAMOATE
ISOCARBOXAZID
LACOSAMIDE
LAMOTRIGINE
LEVETIRACETAM
LEVETIRACETAM IN NAACL (ISO-OS)
LEVOMILNACIPRAN HCL
LISDEXAMFETAMINE DIMESYLATE

**SmartPA Clinical Proposal Form**

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

<b>Psychotropic Medications Continued</b>
LITHIUM CARBONATE
LITHIUM CITRATE
LORAZEPAM
LORAZEPAM IN 5 % DEXTROSE
LORAZEPAM/0.9% SODIUM CHLORIDE
LOXAPINE
LOXAPINE SUCCINATE
LUMATEPERONE TOSYLATE
LURASIDONE HCL
MAPROTILINE HCL
MEPROBAMATE
METHAMPHETAMINE HCL
METHSUXIMIDE
METHYLPHENIDATE
METHYLPHENIDATE HCL
MIDAZOLAM
MIDAZOLAM HCL
MILNACIPRAN HCL
MIRTAZAPINE
MODAFINIL
MOLINDONE HCL
NEFAZODONE HCL
NORTRIPTYLINE HCL
OLANZAPINE
OLANZAPINE PAMOATE
OLANZAPINE/FLUOXETINE HCL
OXAZEPAM
OXCARBAZEPINE
PALIPERIDONE
PALIPERIDONE PALMITATE
PAROXETINE HCL
PAROXETINE MESYLATE
PENTOBARBITAL SODIUM
PERAMPANEL
PERPHENAZINE
PERPHENAZINE/AMITRIPTYLINE HCL
PHENELZINE SULFATE
PHENOBARBITAL
PHENOBARBITAL SODIUM
PHENOBARBITAL/0.9 % SOD CHLOR
PHENYTOIN
PHENYTOIN SODIUM
PHENYTOIN SODIUM EXTENDED
PIMAVANSERIN TARTRATE
PIMOZIDE
PITOLISANT HCL
PREGABALIN
PRIMIDONE
PROTRIPTYLINE HCL
QUETIAPINE FUMARATE
RISPERIDONE
RISPERIDONE MICROSPHERES
RUFINAMIDE
SECOBARBITAL SODIUM

**SmartPA Clinical Proposal Form**

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

<b>Psychotropic Medications Continued</b>
SELEGILINE
<b>SERDEXMETHYLPHEN/DEXMETHYLPHEN</b>
SERTRALINE HCL
SODIUM OXYBATE
<b>SODIUM OXYBATE/CALCIUM OXYBATE/MAGNESIUM</b>
SOLRIAMFETOL HCL
STIRIPENTOL
<b>TETRABENAZINE</b>
THIORIDAZINE HCL
THIOTHIXENE
TIAGABINE HCL
TOPIRAMATE
TRANLYCYPROMINE SULFATE
TRAZODONE HCL
TRIFLUOPERAZINE HCL
TRIMIPRAMINE MALEATE
<b>VALBENAZINE TOSYLATE</b>
VALPROIC ACID
VALPROIC ACID (AS SODIUM SALT)
VENLAFAXINE HCL
VIGABATRIN
VILAZODONE HCL
<b>VILOXAZINE HCL</b>
VORTIOXETINE HYDROBROMIDE
ZIPRASIDONE HCL
ZIPRASIDONE MESYLATE
ZONISAMIDE

**SmartPA Clinical Proposal Form**

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.